Chondroitin sulfate improves synovitis in rabbits with chronic antigen-induced arthritis

Osteoarthritis and Cartilage

Volumn 18, Issue SUPPL. 1, 2010, Pages

  Largo, R ^a   Roman Blas, J A ^a   Moreno Rubio, J ^a   Sanchez Pernaute O ^a   Martinez Calatrava M J ^a   Castaneda S ^a   Herrero Beaumont, G ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Chondroitin sulfate; Chronic arthritis; Inflammation; Synovitis

Indexed keywords

ANTIGEN; CHONDROITIN SULFATE; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CYCLOOXYGENASE 2; MESSENGER RNA; OVALBUMIN; ANTIINFLAMMATORY AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CELL PROLIFERATION; CHRONIC ARTHRITIS; CONTROLLED STUDY; ENDOTHELIUM LESION; FEMORAL ARTERY; HISTOPATHOLOGY; HYPERLIPIDEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN SYNTHESIS INHIBITION; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; SYNOVITIS; SYNOVIUM; TREATMENT OUTCOME; WESTERN BLOTTING; ANIMAL; CHRONIC DISEASE; COMPLICATION; DRUG SCREENING; EXPERIMENTAL ARTHRITIS; MACROPHAGE; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; CHEMOKINE CCL2; CHONDROITIN SULFATES; CHRONIC DISEASE; CYCLOOXYGENASE 2; DRUG EVALUATION, PRECLINICAL; MACROPHAGES; MALE; RABBITS; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 77953787292     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.01.017     Document Type: Article

References (38)

1. Kent P.D., Matteson E.L. Clinical features and differential diagnosis. Rheumatoid Arthritis 2004, 11-25. Lippincott Williams&Wilkins, Philadelphia. 1st edn. E.W. St. Clair, D.S. Pisetsky, B.F. Haynes (Eds.).
2. Bacon P.A., Townend J.N. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis. Arthritis Rheum 2001, 44:707-710. (Editorial).
3. Lago F., Dieguez C., Gomez-Reino J., Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007, 18:313-325.
4. Toh M.L., Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007, 19:284-288.
5. Iwamoto T., Okamoto H., Toyama Y., Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 2008, 275:4448-4455.
6. Manzi S., Wasko M.C. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000, 59:321-325.
7. Park J.Y., Pillinger M.H., Abramson S.B. Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 2006, 119:229-240.
8. Gómez-Hernandez A., Martin-Ventura J.L., Sánchez-Galan E., Vidal C., Ortego M., Blanco-Colio L.M., et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-kappaB. Atherosclerosis 2006, 187:139-149.
9. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
10. Largo R., Sánchez-Pernaute O., Marcos M.E., Moreno-Rubio J., Aparicio C., Granado R., et al. Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: a novel model of atherosclerosis associated with chronic inflammation. Arthritis Rheum 2008, 58:2723-2734.
11. Theocharis A.D., Tsolakis I., Tzanakakis G.N., Karamanos N.K. Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression. Adv Pharmacol 2006, 53:281-295.
12. Monfort J., Pelletier J.P., Garcia-Giralt N., Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulfate on osteoarthritis articular tissues. Ann Rheum Dis 2008, 67:735-740.
13. Leeb B.F., Schweitzer H., Montag K., Smolen J.S. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000, 27:205-211.
14. Volpi N. The pathobiology of osteoarthritis and the rationale for using the chondroitin sulfate for its treatment. Curr Drug Targets Immune Endocr Metabol Disord 2004, 4:119-127.
15. Ronca F., Palmieri L., Panicucci P., Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998, 6(Suppl A):14-21.
16. Bali J.P., Cousse H., Neuzil E. Biochemical basis of the pharmacologic action of chondroitin sulfates on the osteoarticular system. Semin Arthritis Rheum 2001, 31:58-68.
17. Alvarez-Soria M.A., Largo R., Calvo E., Egido J., Herrero-Beaumont G. Differential anticatabolic profile of glucosamine sulfate versus other anti-osteoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblast in culture. Osteoarthritis Cartilage 2005, 13:S153. (Abstract).
18. Omata T., Sagawa Y., Itosaku Y., Inoue N., Tanaka Y. Effects of chondroitin sulphate-C on bradykinin-induced proteoglycan depletion in rats. Arzneimittelforschung 2000, 49:577-581.
19. Chou M.M., Vergnolle N., McDougall J.J., Wallace J.L., Marty S., Teskey V., et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med 2005, 230:255-262.
20. Herrero-Beaumont G., Marcos M.E., Sánchez-Pernaute O., Granados R., Ortega L., Montell E., et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol 2008, 154:843-851.
21. Krenn V., Morawietz L., Haupl T., Neidel J., Petersen I., Konig A. Grading of chronic synovitis-a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract 2002, 198:317-325.
22. Alvarez-Soria M.A., Largo R., Santillana J., Sánchez-Pernaute O., Calvo E., Hernández M., et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006, 65:998-1005.
23. Largo R., Martínez-Calatrava M.J., Sánchez-Pernaute O., Marcos M.E., Moreno-Rubio J., Aparicio C., et al. Effect of a high dose of glucosamine on systemic and tissue inflammation in an experimental model of atherosclerosis aggravated by chronic arthritis. Am J Physiol-Heart Cir Physiol 2009, 297:H268-H276.
24. Howson P., Shepard N., Mitchell N. The antigen induced arthritis model: the relevance of the method of induction to its use as a model of human disease. J Rheumatol 1986, 13:379-390.
25. Benito M.J., Sánchez-Pernaute O., López-Armada M.J., Hernández P., Palacios I., Egido J., et al. Cyclosporin A prevents the histologic damage of antigen arthritis without inducing fibrosis. Arthritis Rheum 2000, 43:311-319.
26. de Vries B.J., van den Berg W.B. Impact of NSAIDS on murine antigen induced arthritis. I. Investigation of antiinflammatory and chondroprotective effects. J Rheumatol Suppl 1989, 18:10-18.
27. van den Berg W.B. Animal models. Rheumatoid Arthritis 2004, 252-267. Lippincott Williams & Wilkins, Philadelphia. 1st edn. E.W. St. Clair, D.S. Pisetsky, B.F. Haynes (Eds.).
28. Firestein G.S. Rheumatoid arthritis: etiology and pathogenesis of rheumatoid arthritis. Kelley's Textbook of Rheumatology 2005, 996-1042. Elsevier Saunders, Philadelphia. 7th edn. E.D. Harris, R.C. Budd, G.S. Firestein, M.C. Genovese, J.S. Sergent, S. Ruddy, C.B. Sledge (Eds.).
29. Palacios I., López-Armada M.J., Hernández P., Sánchez-Pernaute O., Gutiérrez S., Miguelez R., et al. Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. Clin Exp Immunol 1998, 111:588-596.
30. Klimiuk P.A., Sierakowski S., Latosiewicz R., Cylwik J.P., Cylwik B., Skowronski J., et al. Circulating tumour necrosis factor and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003, 62:472-475.
31. Klimiuk P.A., Sierakowski S., Latosiewicz R., Cylwik J.P., Cylwik B., Skowronski J., et al. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin Exp Rheumatol 2003, 21:63-69.
32. Klimiuk P.A., Sierakowski S., Latosiewicz R., Skowronski J., Cylwik J.P., Cylwik B., et al. Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1666-1672.
33. Campo G.M., Avenoso A., Campo S., Ferlazzo A.M., Altavilla D., Calatroni A. Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 2003, 5:R122-R131.
34. 2 in articular cartilage explants. Osteoarthritis Cartilage 2005, 13:387-394.
35. Bassleer C.T., Combal J.P., Bougaret S., Malaise M. Effects of chondroitin sulfate and interleukin-1 beta on human articular chondrocytes cultivated in clusters. Osteoarthritis Cartilage 1998, 6:196-204.
36. Jomphe C., Gabriac M., Hale T.M., Héroux L., Trudeau L.E., Deblois D., et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol 2008, 102:59-65.
37. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
38. Silva F.S., Yoshinari N.H., Castro R.R., Girão V.C., Pompeu M.M., Feitosa J.P., et al. Combined glucosamine and chondroitin sulfate provides functional and structural benefit in the anterior cruciate ligament transection model. Clin Rheumatol 2009, 28:109-117.